Accordingly, we demonstrate that DTX3L overexpression sensitizes prostate cancer cells to synthetic lethality by PARP inhibitors, highlighting that DTX3L overexpression indicates sensitivity to PARP inhibitors in cancers such as prostate cancer. The gene discussed is DTX3L; the disease is cancer.